|
1
|
Della Porta MG, Galli A, Bacigalupo A,
Zibellini S, Bernardi M, Rizzo E, Allione B, van Lint MT, Pioltelli
P, Marenco P, et al: Clinical effects of driver somatic mutations
on the outcomes of patients with myelodysplastic syndromes treated
with allogeneic hematopoietic stem-cell transplantation. J Clin
Oncol. 34:3627–3637. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Cazzola M and Malcovati L: Myelodysplastic
syndromes-coping with ineffective hematopoiesis. N Engl J Med.
352:536–538. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Ades L, Itzykson R and Fenaux P:
Myelodysplastic syndromes. Lancet. 383:2239–2252. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Zhang L, Padron E and Lancet J: The
molecular basis and clinical significance of genetic mutations
identified in myelodysplastic syndromes. Leuk Res. 39:6–17. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Papaemmanuil E, Gerstung M, Malcovati L,
Tauro S, Gundem G, Van Loo P, Yoon CJ, Ellis P, Wedge DC,
Pellagatti A, et al: Clinical and biological implications of driver
mutations in myelodysplastic syndromes. Blood. 122:3616–3627. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Cazzola M, Della Porta MG and Malcovati L:
The genetic basis of myelodysplasia and its clinical relevance.
Blood. 122:4021–4034. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Ogawa S: Genetics of MDS. Blood.
7:1049–1059. 2019. View Article : Google Scholar
|
|
8
|
Tefferi A and Vardiman JW: Myelodysplastic
syndromes. N Engl J Med. 361:1872–1885. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Haferlach T, Nagata Y, Grossmann V, Okuno
Y, Bacher U, Nagae G, Schnittger S, Sanada M, Kon A, Alpermann T,
et al: Landscape of genetic lesions in 944 patients with
myelodysplastic syndromes. Leukemia. 28:241–247. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
McGranahan N and Swanton C: Clonal
heterogeneity and tumor evolution: Past, present, and the future.
Cell. 168:613–628. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Greenberg PL, Stone RM, Al-Kali A, Barta
SK, Bejar R, Bennett JM, Carraway H, De Castro CM, Deeg HJ, DeZern
AE, et al: Myelodysplastic syndromes, version 2.2017, NCCN clinical
practice guidelines in oncology. J Natl Compr Canc Netw. 15:60–87.
2017. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Walter MJ, Shen D, Shao J, Ding L, White
BS, Kandoth C, Miller CA, Niu B, McLellan MD, Dees ND, et al:
Clonal diversity of recurrently mutated genes in myelodysplastic
syndromes. Leukemia. 27:1275–1282. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Ruffalo M, Husseinzadeh H, Makishima H,
Przychodzen B, Ashkar M, Koyuturk M, Maciejewski JP and LaFramboise
T: Whole-exome sequencing enhances prognostic classification of
myeloid malignancies. J Biomed Inform. 58:104–113. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Valent P, Horny HP, Bennett JM, Fonatsch
C, Germing U, Greenberg P, Haferlach T, Haase D, Kolb HJ, Krieger
O, et al: Definitions and standards in the diagnosis and treatment
of the myelodysplastic syndromes: Consensus statements and report
from a working conference. Leuk Res. 31:727–736. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Ernst T, Chase AJ, Score J, Hidalgo-Curtis
CE, Bryant C, Jones AV, Waghorn K, Zoi K, Ross FM, Reiter A, et al:
Inactivating mutations of the histone methyltransferase gene EZH2
in myeloid disorders. Nat Genet. 42:722–726. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Gonzalez Garcia JR and Meza-Espinoza JP:
Use of the international system for human cytogenetic nomenclature
(ISCN). Blood. 108:3952–3953. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Li H and Durbin R: Fast and accurate short
read alignment with burrows-wheeler transform. Bioinformatics.
25:1754–1760. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
McKenna A, Hanna M, Banks E, Sivachenko A,
Cibulskis K, Kernytsky A, Garimella K, Altshuler D, Gabriel S, Daly
M and DePristo MA: The genome analysis toolkit: A mapreduce
framework for analyzing next-generation DNA sequencing data. Genome
Res. 20:1297–1303. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Wang K, Li M and Hakonarson H: ANNOVAR:
Functional annotation of genetic variants from high-throughput
sequencing data. Nucleic Acids Res. 38:e1642010. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Xu Y, Li Y, Xu Q, Chen Y, Lv N, Jing Y,
Dou L, Bo J, Hou G, Guo J, et al: Implications of mutational
spectrum in myelodysplastic syndromes based on targeted
next-generation sequencing. Oncotarget. 8:82475–82490.
2017.PubMed/NCBI
|
|
21
|
Li B, Liu J, Jia Y, Wang J, Xu Z, Qin T,
Shi Z, Song Z, Peng S, Huang H, et al: Clinical features and
biological implications of different U2AF1 mutation types in
myelodysplastic syndromes. Genes Chromosomes Cancer. 57:80–88.
2018. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Xu F, Wu LY, He Q, Wu D, Zhang Z, Song LX,
Zhao YS, Su JY, Zhou LY, Guo J, et al: Exploration of the role of
gene mutations in myelodysplastic syndromes through a sequencing
design involving a small number of target genes. Sci Rep.
7:431132017. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Wu L, Song L, Xu L, Chang C, Xu F, Wu D,
He Q, Su J, Zhou L, Xiao C, et al: Genetic landscape of recurrent
ASXL1, U2AF1, SF3B1, SRSF2, and EZH2 mutations in 304 chinese
patients with myelodysplastic syndromes. Tumour Biol. 37:4633–4640.
2016. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Inoue D, Kitaura J, Matsui H, Hou HA, Chou
WC, Nagamachi A, Kawabata KC, Togami K, Nagase R, Horikawa S, et
al: SETBP1 mutations drive leukemic transformation in ASXL1-mutated
MDS. Leukemia. 29:847–857. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Arber DA, Orazi A, Hasserjian R, Thiele J,
Borowitz MJ, Le Beau MM, Bloomfield CD, Cazzola M and Vardiman JW:
The 2016 revision to the world health organization classification
of myeloid neoplasms and acute leukemia. Blood. 127:2391–2405.
2016. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Muto T, Sashida G, Oshima M, Wendt GR,
Mochizuki-Kashio M, Nagata Y, Sanada M, Miyagi S, Saraya A, Kamio
A, et al: Concurrent loss of Ezh2 and Tet2 cooperates in the
pathogenesis of myelodysplastic disorders. J Exp Med.
210:2627–2639. 2013. View Article : Google Scholar : PubMed/NCBI
|
